<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03019757</url>
  </required_header>
  <id_info>
    <org_study_id>2014H0415</org_study_id>
    <nct_id>NCT03019757</nct_id>
  </id_info>
  <brief_title>Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease</brief_title>
  <official_title>Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Douglas Scharre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Avid Radiopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mangurian Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to characterize the clinical, neuropsychological, polysomnographic, and
      neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and
      Parkinsons' Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will use structural and functional MRIs, daTscans, fluorodeoxyglucose (FDG) PET
      scans, Amyvid PET scans, polysomnographs, neuropsychological testing, cerebrospinal fluid in
      willing participants to distinguish between a diagnosis of Alzheimer's disease, Lewy Body
      dementia, and Parkinson's Disease. All subjects will have a clinical evaluation, physical
      examination including vital signs and orthostatic blood pressures and pulses, neurological
      examination including UPDRS evaluation, genetic blood sample collection, neuropsychological
      testing, polysomnogram, and neuroimaging. The study partner will also be interviewed for
      completion of all of the behavioral and functional measures.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mini Mental State Examination (MMSE-1)</measure>
    <time_frame>Baseline</time_frame>
    <description>Global neuropsychological measure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wechsler Adult Intelligence Scale 4th edition (WAIS-4) Vocabulary</measure>
    <time_frame>Baseline</time_frame>
    <description>Neuropsychological measure of premorbid IQ estimate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wechsler Adult Intelligence Scale 4th edition (WAIS-4) Digit Span</measure>
    <time_frame>Baseline</time_frame>
    <description>Neuropsychological measure of attention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wechsler Adult Intelligence Scale 4th edition (WAIS-4) Block Design</measure>
    <time_frame>Baseline</time_frame>
    <description>Neuropsychological measure of visuospatial perception/ reasoning</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wechsler Adult Intelligence Scale 4th edition (WAIS-4) Matrix Reasoning</measure>
    <time_frame>Baseline</time_frame>
    <description>Neuropsychological measure of executive functioning</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wechsler Adult Intelligence Scale 4th edition (WAIS-4) Reliable Digits (embedded measure)</measure>
    <time_frame>Baseline</time_frame>
    <description>Neuropsychological measure of effort</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wechsler Memory Scale 3rd ed. (WAIS-3) Spatial Span</measure>
    <time_frame>Baseline</time_frame>
    <description>Neuropsychological measure of attention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wechsler Memory Scale 3rd ed. (WAIS-3) Logical Memory 1 &amp; 2</measure>
    <time_frame>Baseline</time_frame>
    <description>Neuropsychological measure of memory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trail Making Test A</measure>
    <time_frame>Baseline</time_frame>
    <description>Neuropsychological measure of executive functioning/psychomotor processing speed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trail Making Test B</measure>
    <time_frame>Baseline</time_frame>
    <description>Neuropsychological measure of executive functioning</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Boston Naming Test</measure>
    <time_frame>Baseline</time_frame>
    <description>Neuropsychological measure of language</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Controlled Oral Word Association Test (COWAT)- Animal Naming</measure>
    <time_frame>Baseline</time_frame>
    <description>Neuropsychological measure of language/verbal fluency</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Judgment of Line Orientation Standardized Test</measure>
    <time_frame>Baseline</time_frame>
    <description>Neuropsychological measure of visuospatial perception/ reasoning</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brief Visuospatial Memory Test (BVMT)</measure>
    <time_frame>Baseline</time_frame>
    <description>Neuropsychological measure of memory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>California Verbal Learning Test (CVLT-2)</measure>
    <time_frame>Baseline</time_frame>
    <description>Neuropsychological measure of memory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wisconsin Card Sorting Task</measure>
    <time_frame>Baseline</time_frame>
    <description>Neuropsychological measure of executive functioning</description>
  </primary_outcome>
  <primary_outcome>
    <measure>California Verbal Learning Test (CVLT-2) Forced Choice (embedded measure)</measure>
    <time_frame>Baseline</time_frame>
    <description>Neuropsychological measure of effort</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Self Administered Gerocognitive Examination- A brief cognitive assessment instrument for mild cognitive impairment and early dementia</measure>
    <time_frame>Baseline</time_frame>
    <description>Global neuropsychological measure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apolipoprotein E (APOE) Genotyping of a whole blood sample</measure>
    <time_frame>Baseline</time_frame>
    <description>10 ml of whole blood will be drawn for APOE genotyping</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Dementia Rating Scale (CDR)</measure>
    <time_frame>Baseline</time_frame>
    <description>Global cognitive and functional measure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Activities of Daily Living (ADL) Standardized Scale</measure>
    <time_frame>Baseline</time_frame>
    <description>Functional measure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mayo Fluctuations Scale</measure>
    <time_frame>Baseline</time_frame>
    <description>Behavioral measure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuropsychiatric Inventory (NPI)</measure>
    <time_frame>Baseline</time_frame>
    <description>Behavioral measure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Beck Depression Inventory 2nd ed.</measure>
    <time_frame>Baseline</time_frame>
    <description>Behavioral measure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Modified Somatic Perception Questionnaire</measure>
    <time_frame>Baseline</time_frame>
    <description>Behavioral measure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Epworth Sleepiness Scale</measure>
    <time_frame>Baseline</time_frame>
    <description>Sleep measure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mayo Sleep Questionnaire-Informant</measure>
    <time_frame>Baseline</time_frame>
    <description>Sleep measure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Outcomes of Sleep Questionnaire-10</measure>
    <time_frame>Baseline</time_frame>
    <description>Sleep measure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part III and IV of the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS)</measure>
    <time_frame>Baseline</time_frame>
    <description>Gait, Mobility, and Coordination Measure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Berg Balance Scale (BBS)</measure>
    <time_frame>Baseline</time_frame>
    <description>Gait, Mobility, and Coordination Measure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Florbetapir (F18-AV-45) positron emission tomography (amyloid PET)</measure>
    <time_frame>Baseline</time_frame>
    <description>Imaging to determine extent of amyloid deposition</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Single-photon emission computed tomography (SPECT) with the radioligand [123I]FP-CIT</measure>
    <time_frame>Baseline</time_frame>
    <description>Functional imaging of the dopamine transporter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positron emission tomography with 2-(18F) fluoro-2-deoxy-d-glucose (FDG-PET)</measure>
    <time_frame>Baseline</time_frame>
    <description>Imaging to determine total and regional cerebral glucose metabolism</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain MRI</measure>
    <time_frame>Baseline</time_frame>
    <description>Imaging including a resting state functional MRI, diffusion tensor imaging, and anatomic imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Polysomnogram</measure>
    <time_frame>Baseline</time_frame>
    <description>participants will have an overnight standard clinical polysomnogram with added limb leads assessing for presence of sleep apnea, periodic limb movements, and rapid eye movement (REM) sleep characteristics</description>
  </primary_outcome>
  <other_outcome>
    <measure>Lumbar Puncture to obtain cerebrospinal fluid (CSF) that will be stored for future potential evaluation of biomarkers</measure>
    <time_frame>Baseline</time_frame>
    <description>Optional outcome measure which will be done to obtain samples of CSF</description>
  </other_outcome>
  <other_outcome>
    <measure>Post-mortem brain donation to The Ohio State University Neurodegenerative Disease Brain Tissue Repository, for clinicopathological correlations</measure>
    <time_frame>Post mortem</time_frame>
    <description>Optional outcome measure for patients post-mortem to asses for neuropathologic conditions</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Lewy Body Dementia</condition>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Alzheimer's disease</arm_group_label>
    <description>Individuals with a clinical diagnosis of Alzheimer's disease will undergo the interventions including DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, and Clinical Assessment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lewy Body dementia</arm_group_label>
    <description>Individuals with a clinical diagnosis of Lewy Body Dementia will undergo the interventions including DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, and Clinical Assessment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parkinson's disease</arm_group_label>
    <description>Individuals with a clinical diagnosis of Parkinson's disease will undergo the interventions including DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, and Clinical Assessment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>DaTscan</intervention_name>
    <description>A functional imaging of the dopamine transporter using the radioligand [123I]FP-CIT</description>
    <arm_group_label>Alzheimer's disease</arm_group_label>
    <arm_group_label>Lewy Body dementia</arm_group_label>
    <arm_group_label>Parkinson's disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>F18-AV-45</intervention_name>
    <description>A brain scan to to measure the extent of amyloid deposition</description>
    <arm_group_label>Alzheimer's disease</arm_group_label>
    <arm_group_label>Lewy Body dementia</arm_group_label>
    <arm_group_label>Parkinson's disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>FDG-PET</intervention_name>
    <description>a brain scan measuring total and regional cerebral glucose metabolism wtih positron emission tomographs with 2-(18F)</description>
    <arm_group_label>Alzheimer's disease</arm_group_label>
    <arm_group_label>Lewy Body dementia</arm_group_label>
    <arm_group_label>Parkinson's disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>APOE genotype</intervention_name>
    <description>10 ml of whole blood will be drawn and shipped to Athena Diagnostics for genetic testing.</description>
    <arm_group_label>Alzheimer's disease</arm_group_label>
    <arm_group_label>Lewy Body dementia</arm_group_label>
    <arm_group_label>Parkinson's disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Polysomnogram</intervention_name>
    <description>Overnight sleep study</description>
    <arm_group_label>Alzheimer's disease</arm_group_label>
    <arm_group_label>Lewy Body dementia</arm_group_label>
    <arm_group_label>Parkinson's disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Clinical Assessment</intervention_name>
    <description>Clinical assessments include cognitive, behavioral, and motor evaluations</description>
    <arm_group_label>Alzheimer's disease</arm_group_label>
    <arm_group_label>Lewy Body dementia</arm_group_label>
    <arm_group_label>Parkinson's disease</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Participants will have the option to participate in a lumbar puncture sub-study as well as a
      brain donation program. These samples will be retained in the Buckeye Biospecimen Repository
      or the Buckeye Brain Bank, respectively.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects must have a clinical diagnosis of either Alzheimer's disease, Lewy Body Dementia,
        or Parkinson's disease.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must meet the standard clinical criteria of the syndromes of interest

          -  All subjects must have enough cognitive abilities to complete study procedures, which
             will be operationally defined as having a Mini Mental State Examination (MMSE) score
             greater or equal to 10.

          -  Subjects must be on stable cognitive and psychoactive medication regimen for the
             preceding four weeks of enrollment.

          -  Subjects must have a responsible study partner that either lives with them or is in
             regular contact with them at least 4 out of 7 days per week.

          -  Subjects must have visual and auditory acuity adequate for testing.

        Exclusion Criteria:

          -  Any other condition (other than the primary diagnosis), which in the opinion of the
             investigators might contribute to the syndrome of dementia or complicate its
             assessment.

          -  active medical disorder that could preclude participation in this protocol

          -  Women who are pregnant or are breast feeding

          -  severe renal impairment as defined by glomerular filtration rate (GFR) less than 30
             (may have increased radiation exposure with the DaTscan).

          -  Subjects in whom English is not the 1st language

          -  Subjects with educational level less than 12 years

          -  Subjects who have ever participated in an experimental study with an amyloid targeting
             agent unless it can be documented that the subject received only placebo during the
             course of the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas W Scharre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Icenhour</last_name>
    <phone>614-293-6882</phone>
    <email>jennifer.icenhour@osumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Icenhour</last_name>
      <phone>614-293-6882</phone>
      <email>jennifer.icenhour@osumc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2015</study_first_submitted>
  <study_first_submitted_qc>January 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2017</study_first_posted>
  <last_update_submitted>September 18, 2017</last_update_submitted>
  <last_update_submitted_qc>September 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Douglas Scharre</investigator_full_name>
    <investigator_title>Professor, Clinical</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Lewy Body Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

